

January 25, 2024

**Best Practices for Bioanalytical and Immunogenicity Assessment aspects of CAR-T Cellular Therapies Development: An Industry Perspective**

Audience Question:

How would you characterise positive control antibody and also in vitro synthesised therapeutic protein to be used as antigen?

Answer:

The approach to characterize positive control antibody will be very similar to what one would do for other biologics. The extracellular domain of CAR (generally invitro synthesized) is used as the antigen to generate your positive control as this is the portion that is outside of the cell.